Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery
Exalpha Biologicals, Inc.

Phosphotyrosine FITC conjugate

  • Product Code: X1017
  • Size: 100 µg
  • Price (USD): $199

Cat #

X1017		 Quantity:      

Data Sheet

Product Name

Phosphotyrosine FITC conjugate


Mouse anti phosphotyrosine, PY20, FITC conjugate







Product Type

Monoclonal Antibody




Western Blot, Immunoprecipitation, Enzyme Immunoassay, Immunofluorescence


100 µg

Price (USD)



The role of tyrosine phosphorylation in transduction of the mitogenic signal from transmembrane receptors and in transformation by oncogene tyrosine kinases has been the subject of intense investigation for several years. While the phosphorylation of specific tyrosine residues has been shown to be a primary mechanism of signal transduction during normal mitogenesis, cell cycle progression and oncogenic transformation, its role in other areas such as differentiation and gap junction communication, is a matter of active and ongoing research. Antibodies that specifically recognize phosphorylated tyrosine residues have proved to be invaluable to the study of tyrosine -phosphorylated proteins and the biochemical pathways in which they function. The fluorescein (FITC) conjugate of clone PY20 anti-phosphotyrosine is especially useful for the detection of these P-Tyr proteins in immunohistochemical and immunocytochemical protocols in situations wherein the use of a secondary antibody would complicate detection of the protein(s) of interest.


Hybridoma produced from Balb/C mice immunized with phosphotyrosine coupled to carrier protein.


Provided as sterile solution in 20 mM sodium phosphate, 150 mM sodium chloride, 50% glycerol, 3 mM sodium azide

Customer Storage

Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Target Molecular Weight


Product Specific References

This product has been used in:

1. Tahiri, A., et al. 'Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma.' PLoS One, 8, e72692 (2013) 2. Galvani, E., et al. 'Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer.' Neoplasia, 15, 61-72 (2013)